Eli Lilly and Company: Sepsis trials
The registry lists 12 Sepsis studies with Eli Lilly and Company as lead sponsor. 0 are open to participants now and 3 have results posted.
Phase 1 1Phase 2 2Phase 3 4Phase 4 5No phase 1(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Efficacy and Safety of Drotrecogin Alfa (Activated) in Adult Patients With Septic ShockCompletedNCT00604214Phase 3Results posted
- Evaluate Protein C Levels in Severe Sepsis Patients on Drotrecogin Alfa (Activated)CompletedNCT00386425Phase 2Results posted
- Hemodynamic and Perfusion Response to Drotrecogin Alfa (Activated) in Patients With Septic ShockCompletedNCT00279214Phase 4Results posted
- Follow-up Data of Patients Treated With XIGRIS® in FranceCompletedNCT00803231
- An Open Label Study of Severe Sepsis in AdultsCompletedNCT00568893Phase 4
- The Study of Drotrecogin Alfa (Activated) in Adult Patients With Severe Sepsis at a Low Risk of DeathCompletedNCT00568737Phase 3
- Extended Therapy of Drotrecogin Alfa (Activated) 4 vs 7 Days InfusionCompletedNCT00190788Phase 3
- A Safety Evaluation of Drotrecogin Alfa (Activated) in Patients With Blood Cancer, Severe Infection Related to Bone Marrow TransplantationCompletedNCT00067730Phase 4
- A Trial of Heparin in Patients With Severe Sepsis Who Are Undergoing Treatment With Drotrecogin Alfa (Activated)CompletedNCT00049777Phase 4
- Investigation of the Efficacy and Safety of Drotrecogin Alfa (Activated) in Pediatric Severe SepsisCompletedNCT00049764Phase 3
- The Study of Drotrecogin Alfa (Activated) in a Subpopulation of Adult Patients With Severe SepsisCompletedNCT00045760Phase 4
- A Phase IIb Study to Determine the Efficacy and Safety of the Study Drug in Patients With Severe SepsisCompletedNCT00034476Phase 1/2